Inantol (Fluticasone Propionate, Salmeterol)

Fluticasone propionate activates glucocorticoid receptors in airway cells, suppressing inflammatory pathways and decreasing mucus production. Salmeterol selectively stimulates β2‑adrenergic receptors, raising cyclic AMP levels that relax bronchial smooth muscle. Together, they reduce airway inflammation and provide sustained bronchodilation for up to 12 hours.

The prescribed dose of Inantol is individualized by a healthcare professional based on the severity of asthma or COPD, patient age, and response to therapy. The prescriber determines the number of inhalations per day and the total daily dose, which should be followed exactly as instructed on the prescription label.

The safety of Inantol in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and alternatives with their physician.

To request Inantol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Inantol combines an inhaled corticosteroid with a long‑acting β2‑agonist, offering both anti‑inflammatory and bronchodilator effects in a single device. Compared with single‑component inhalers, it reduces the need for multiple devices, improves adherence, and provides consistent dosing. Alternatives may include separate corticosteroid and LABA inhalers or combination products with different potency or device types.

Inantol should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the inhaler cap tightly closed when not in use and avoid exposing it to extreme temperatures, which could affect aerosol performance.

Inantol is delivered via an inhalation aerosol device. The patient exhales fully, places the mouthpiece in the mouth, and inhales slowly and deeply while actuating the inhaler. After each inhalation, the patient should hold their breath for about 10 seconds to allow optimal drug deposition, then rinse the mouth to reduce local side effects.

Serious risks include paradoxical bronchospasm, which can worsen breathing difficulty, and systemic effects such as adrenal suppression or severe allergic reactions (anaphylaxis). Patients should be educated to seek immediate medical attention if they experience sudden wheezing, swelling, rash, or signs of infection while using the inhaler.

Inantol is contraindicated in individuals with a known hypersensitivity to fluticasone, salmeterol, or any component of the inhaler formulation. It should also be avoided in patients who have experienced severe paradoxical bronchospasm with similar medications. Clinicians must assess each patient’s medical history before initiating therapy.